<SEC-DOCUMENT>0001193125-19-166285.txt : 20190605
<SEC-HEADER>0001193125-19-166285.hdr.sgml : 20190605
<ACCEPTANCE-DATETIME>20190605171532
ACCESSION NUMBER:		0001193125-19-166285
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190530
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190605
DATE AS OF CHANGE:		20190605

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		19880626

	BUSINESS ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d758685d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): May&nbsp;30, 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-36740</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">77-0357827</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(IRS Employer<BR>Identification No.)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>409 Illinois Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San
Francisco, CA 94158 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (415) <FONT STYLE="white-space:nowrap">978-1200</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Former name or former address, if changed since last report: Not Applicable </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Securities registered pursuant to Section&nbsp;12(b) of the Act: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of each class</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trading Symbol</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Name of each exchange on which
registered</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock, $0.01 par value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>FGEN</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The Nasdaq Global Select Market</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <U>Appointment of New Director</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective as of June&nbsp;10, 2019, the Board of Directors (the &#147;Board&#148;) of FibroGen,&nbsp;Inc. (the &#147;Company&#148;) appointed
Suzanne Blaug as a Class&nbsp;II director of the Company, upon the recommendation of the Nominating and Corporate Governance Committee. A copy of the Company&#146;s press release announcing Ms.&nbsp;Blaug&#146;s appointment to the Board is attached
as Exhibit&nbsp;99.1 to this report. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Blaug will hold office for the term expiring at the Company&#146;s 2022 annual meeting of
stockholders and she will receive compensation as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director of the Company under the Company&#146;s <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy, as amended.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ms.&nbsp;Blaug and the Company have also entered into the Company&#146;s standard Indemnity Agreement, effective June&nbsp;5, 2019, a
form of which is filed as Exhibit 10.26 with the Company&#146;s registration statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> as amended, filed with the SEC on October&nbsp;23, 2014. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.07</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Submission of Matters to a Vote of Security Holders. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the 2019 annual meeting of stockholders of FibroGen, Inc. held on June&nbsp;5, 2019, the stockholders voted on the three proposals listed
below. The proposals are described in detail in the Company&#146;s definitive proxy statement for the 2019 annual meeting, filed with the Securities and Exchange Commission on April&nbsp;23, 2019.&nbsp;The results of the matters voted upon at the
meeting were: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="97%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">All of the Class&nbsp;II nominees of the Board were elected to hold office until the Company&#146;s
2022 annual meeting of stockholders. The nominees were: (i)&nbsp;Jeffrey L. Edwards: 58,205,199 shares of Common Stock voted for, 495,694 withheld, and 15,013,904 broker <FONT STYLE="white-space:nowrap">non-votes;</FONT> (ii)&nbsp;Rory B. Riggs:
56,396,919 shares of Common Stock voted for, 2,303,974 withheld, and 15,013,904 broker <FONT STYLE="white-space:nowrap">non-votes;</FONT> and (iii)&nbsp;Roberto Pedro Rosenkranz, Ph.D., M.B.A.: 57,593,920 shares of Common Stock voted for, 1,106,973
withheld, and 15,013,904 broker <FONT STYLE="white-space:nowrap">non-votes.</FONT></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">The term of office of Class&nbsp;III directors Thomas F. Kearns Jr., Kalevi Kurkij&auml;rvi, Ph.D., Gerald Lema, and
Toshinari Tamura, Ph.D. continues until the Company&#146;s 2020 annual meeting of stockholders. The term of office of Class&nbsp;I directors Thomas B. Neff, Jeffrey W. Henderson, Maykin Ho, Ph.D., and James A. Schoeneck continues until the
Company&#146;s 2021 annual meeting of stockholders.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">The stockholders approved, on an advisory basis, the compensation of the Company&#146;s named
executive officers, as disclosed in the 2019 definitive proxy statement:&nbsp;57,771,549 shares of Common Stock voted for, 870,314 against, and 59,030 abstaining.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">The stockholders ratified the selection by the Audit Committee of the Board of
PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the year ending December&nbsp;31, 2019: 73,347,894 shares of Common Stock voted for, 209,480 against, and 157,423 abstaining.</P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d758685dex991.htm">Press Release titled &#147;FibroGen Appoints Suzanne Blaug to Board of Directors&#148; dated June&nbsp;5, 2019 </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>F<SMALL>IBRO</SMALL>G<SMALL>EN</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: June&nbsp;5, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Lowenstein</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael Lowenstein</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Legal Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d758685dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g758685g86t12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIBROGEN APPOINTS SUZANNE BLAUG TO BOARD OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SAN FRANCISCO, June&nbsp;5, 2019 &#151; FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutics, today announced the appointment of Suzanne Blaug as an independent director to FibroGen&#146;s Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Suzanne Blaug joins the FibroGen Board of Directors at a key time for the company. Her experience in commercial strategy and management and bringing new
biopharmaceutical products to market in numerous therapeutic areas globally will be an invaluable asset as we and our partners advance roxadustat towards regulatory milestones and commercialization in the U.S. and international markets, and as our
pamrevlumab program enters Phase 3 clinical development in multiple therapeutic areas,&#148; said Thomas B. Neff, Chief Executive Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am
excited to join FibroGen&#146;s Board as the company prepares for critical next steps in the regulatory and commercial development of roxadustat for the treatment of anemia associated with CKD and in other important applications in the treatment of
anemia. I am also quite impressed by the breadth of development opportunities for FibroGen&#146;s lead anti-fibrosis therapeutic, which has demonstrated promising potential in several disease applications,&#148; Ms.&nbsp;Blaug added. &#147;I look
forward to working with Tom Neff and the entire Board of Directors in growing value for shareholders and advancing these innovative therapeutics to patients.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suzanne Blaug has more than 30 years of strategic and commercial experience in the biopharmaceutical industry. She has successfully brought new drugs to
market at the global, regional, and local country levels in multiple therapeutic areas including Oncology, Cardiovascular, Immunology, Nephrology, Infectious Diseases, Neurology, and Psychiatry.&nbsp;Ms.&nbsp;Blaug most recently served as Senior
Vice President, Global Marketing and Commercial Development at Amgen Inc. from 2012 to 2018. From 2004 until 2012, she was at Johnson&nbsp;&amp; Johnson, where she held several positions including Head of Janssen Alzheimer Immunotherapy, Vice
President Strategic Marketing and New Business Development at Janssen Europe, and Area Managing Director&#151;UK, Italy, and Greece. Ms.&nbsp;Blaug started her career at Bristol-Myers Squibb in 1983, where she held numerous marketing, strategic, and
general management positions in the U.S., Europe, Australia, and New Zealand. Ms.&nbsp;Blaug is currently a senior advisor at McKinsey&nbsp;&amp; Company, and she serves on the Healthcare at Kellogg Advisory Council at Northwestern University, as
well as the Center for the Business of Healthcare Corporate Advisory Board at the University of North Carolina. Ms.&nbsp;Blaug received her Bachelor of Science degree from the University of North Carolina at Chapel Hill, and her Master of Business
Administration from the Kellogg School of Management at Northwestern University. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About FibroGen </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc., headquartered in San Francisco, California, with subsidiary offices in Beijing and Shanghai, People&#146;s Republic of China, is a leading
biopharmaceutical company discovering and developing a pipeline of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutics.&nbsp;The company applies its pioneering expertise in hypoxia-inducible
factor (HIF), connective tissue growth factor (CTGF) biology, and clinical development to advance innovative medicines </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Page 1 of 2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company&#146;s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity,
completing worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application (NDA) now approved by the National Medical Products Administration (NMPA) in China. Our partner Astellas
submitted an NDA for the treatment of anemia in CKD patients on dialysis in Japan in September 2018, which is currently under review by the Pharmaceuticals and Medical Devices Agency (PMDA). Roxadustat is in Phase 3 clinical development in the U.S.
and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS).&nbsp;Pamrevlumab, an anti-CTGF human monoclonal antibody, is advancing towards Phase 3 clinical development for the treatment of idiopathic
pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit <U>www.fibrogen.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This release contains
forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development of roxadustat and pamrevlumab, the potential safety and efficacy profile of our product candidates, and our clinical and
regulatory plans. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as
&#147;may,&#148; &#147;will&#148;, &#147;should,&#148; &#147;on track,&#148; &#147;could,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential,&#148;
&#147;continue&#148; and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to
the continued progress and timing of our various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2018, and our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarter ended March&nbsp;31, 2019 filed with the Securities
and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to
update any forward-looking statement in this press release, except as required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Karen L. Bergman </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Investor Relations and
Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 (415) <FONT STYLE="white-space:nowrap">978-1433</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>ir@fibrogen.com </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Page 2 of 2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g758685g86t12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g758685g86t12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !# 0D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V:BBH);N"
M!]LTJQ\9RYP/SZ=C0#=B8D*,D@#U-+3/DFC_ (71A]015)':R9U7=):QD*1U
M:'C/XCD>X_D!<DOK@HT-M$Q$]PQ52/X0.6;\!^I%6Q6#'<L;C^VF8&S8^2,]
M%ASQ)GW;D_[.#VJ^\SWCQA=\=L[8##AI."?P7CKU/M3:(B[ZFA15*_E >UMA
MG=/*!P<?*HW'^6/QJY2*3N["T444#"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "H7DB,H@DQEU)"L.&'>B>Y2W*^8
M&"L<%\<+]?2F78AFM"[S+&B_.LVX +Z'/2@5^ACR6EC;ZL1%-]E26+*FWEV!
M74\C XY##J.QJIJ>H7-C:21M?0,D[E3)(FQ@@'+;UXZ<=.I%37>IRSVHN+:!
M(GLV$TDSC"E>02B\%@5)QT''4T_0-/-U<W&H7V^9TE>.W,I!V@'E@!P"3Z>E
M6N[,)PU2CI<SFU0&+S#IMPMB1_Q[R K!@#[V_I^&,?C5O3[N6]M%$VJH(H'5
M-T'&]#]T[SR3V. .0:ZBN=UW35L9(]2L=]N1(JW AP REN&*G@[3@_0FA-,M
MJ<5IJ36,5DFO2O R?NH0FYGW,[,<GDG)P OYUK&Y4W*PH"[$;F(/"#MGZ]OQ
MKG['49K2S\^ZM5E>[8S+-'\PP>[+U4!<=,UN:<D"VJM;RI,'Y:5<?.?P_EVI
M204I71;KPQ?%'B:YO7@M=2OI9"[;8XQN) )Z "O<Z\5\ ?\ )0+?ZS?^@M5T
M]FRI;H/[2\<?W]8_[\'_ .)JSINH>,VU2S6X?5O),Z"3="0-NX9SQTQ7L%%+
MVGD/E\SS7Q]XB\0Z9XDB@T]Y8;<(K0B./<)F/4'@YYXQ6SX\U34=/\'VMU!,
M]I>/+&)/+/0E267\ZJ^-/'&H>'-<CL[2"UDC:%9,RJQ.22.Q'I4OQ28MX/@8
M]3<QG_QUJ:7PZ"[FC\/[^ZU+PK%<7T[SS&60%WZD!N*Z:O(=$\=CPYX4MK&R
MMUN+UI)&;>3M0%CC@<DGTIR_$OQ'93*U[:0%&Z)) T>?H<T.FVW8%)6/7**Q
M?#'B>T\3V#3VX:.6,[986.2A_J#V-<C)\3;JR\1W5K>VT!LH)98\QAO,.W.W
MOCD@?G4*#>A7,CTBBO)K?XB^)=4U**&QM[51/($CC\IF'7NV?S-='XJ^(<>@
MS&QM(DNKY /-8DB.,XZ>I/M^M/V<KV%S([:BO(Q\2O$EN1<7%G ;=CQNMW13
M]&S7=^%?%]IXHMW$:F"[B&9(&.2!Z@]Q0X-:@I)E_7M<M?#VF/>WC':/E1%^
M](W917D]WXI\2^+;XV]B9T5NEM:$J /]INOXDXJU\4M3>Y\1K9Y/DV<0PN?X
MFY)_+ KT#P7H46A^';=0@%Q.@EG?')8C./H.E4K0C?J+=V/.)O#'C/3X_M.+
MT[>?W5WO8?@&S6OX.^(=X;^'3M:+3I*WEQS!/G5NP8#J/?J*]/K.A\/:;;ZU
M+JT=J@O95VM)Z>I [$]SWI<Z:U0^6VQI45G:YK=IH&F27MZQ"+PJK]YV/11[
MUYT_Q&\1ZM=,NCZ>@0?P1PM,P'N>GZ5,8-C;2/5J*\OL/B;J>GWPM_$-@ F?
MF*QF.1!Z[3UKLO$NOOI?A:35M.\F;A&C+Y*L&(&>,=C0X-.P*29O45YK%\5G
M&C!I+2.75'D*K'&"(PO8GJ3]!Z=JHI\4-<M+L?;[" H3GRC&\38]B3_2G[.0
MN9'K%%9^AZS;:_I<5]9D['X*M]Y&'53[UH5!0A (P>AK)N="A#K-:,L#1DN(
MW&Z'/J4Z ^XQ6O5.>.2[E,)!2W3EC_ST/I_N^OKT]::=B913W,*_U%G@^UW\
M'DB%"UNV"T4S=/F/8'C 8#U]*O>%)5_L9+7&)+-C"X..W(/'7((YJ6_CFFN[
M*S:571V,L@*=53GGGIN*UC7T;Z1<_:;2XM[*1Y#$T:@E7'524YXSQ\H'WJK1
MJQC>2G?>QUU8_BF6+^QVM96Q]L80#IP#U//' !ZU1'B'5]@0:9&TQXP7*MG&
M?]6><>^:IV3)J6I+/J-W#<3(ZQ1QRH4"'JQ5#[_+DY/RT*-M1U*B:Y>Y9TR]
MN! +JUA1]XVW$I3$43 X.P#EER#G''?/6M2/0PA>>.[F2\D.YIH\!3]4^Z1]
M>?>E@CF@U.YMS, )P+A"(^_W7')]E/XU<M8'M6:)<&W S&,\IZK]/3\J39KR
MI[H=;_:!N6X$9Q]UTS\WX=OSKP/3]-N]7ULV=@0+B1W*Y?:.,D\_2OH.O%?
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M>)FWE5S@GIGGZ"K$\$=S;R03('BD4HZGN#P14E%(#-TOP]I>B/(VFV<=NT@
M<IGD#IU^M:-+11>X!1110 4E%% #8XTA0)&H5%Z =J?110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
$ '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
